How Freud Explains the Tudors: Psychological Motivations and Historical Understanding of Tutor England\u27s Religious Schism

My thesis fuses several scholastic and intellectual interests that have been a part of me for many years now. History, religion, and literature are all fields I contemplated studying seriously. Furthermore, examining the motivations and reasons behind actions - a more psychological slant - has been an angle that has accompanied my fixation with these three fields. In Tudor England, I found the glorious intersection of these four paths, and I think what captivated me more than anything about this thesis, was the way in which they all worked together to create an overarching paradigm for a whole era

Robustness of Yu-Shiba-Rusinov resonances in presence of a complex superconducting order parameter

Robust quantum systems rely on having a protective environment with minimized relaxation channels. Superconducting gaps play an important role in the design of such environments. The interaction of localized single spins with a conventional superconductor generally leads to intrinsically extremely narrow Yu-Shiba-Rusinov (YSR) resonances protected inside the superconducting gap. However, this may not apply to superconductors with nontrivial, energy dependent order parameters. Exploiting the Fe-doped two-band superconductor NbSe$_2$, we show that due to the nontrivial relation between its complex valued and energy dependent order parameters, YSR states are no longer restricted to be inside the gap. They can appear outside the gap (i. e. inside the coherence peaks), where they can also acquire a substantial intrinsic lifetime broadening. T-matrix scattering calculations show excellent agreement with the experimental data and relate the intrinsic YSR state broadening to the imaginary part of the host's order parameters. Our results suggest that non-thermal relaxation mechanisms contribute to the finite lifetime of the YSR states, even within the superconducting gap, making them less protected against residual interactions than previously assumed. YSR states may serve as valuable probes for nontrivial order parameters promoting a judicious selection of protective superconductors.Comment: 11 pages, 8 figures, including supporting informatio

The VITROVAC Cavity for the TERA/PIMMS Medical Synchrotron

A proton and light-ion medical synchrotron is characterised by a large frequency swing for the RF between the injection and the top energy. For this purpose, a VITROVAC®-loaded RF cavity has been developed for the Proton-Ion Medical Machine Study (PIMMS) at CERN, and for TERA, the Italian project of a proton and light-ion synchrotron for cancer therapy, based on the PIMMS study. The main features are a large frequency swing, particularly extended to the low frequency range, a very large relative permeability and a low Q factor. The total power needed is less than 100 kW, while a very small bias power is required for the frequency tuning. The main mechanical characteristics are compactness (less than 1.5 m), and simplicity of construction. As a result, the requirements of the medical synchrotron are comfortably satisfied, namely: 0.4 to 3 MHz swing, 3 kV peak voltage at a repetition rate of less than 1 s

syn-Dispiro­[1,3-dioxolane-2,17′-penta­cyclo­[12.2.1.16,9.02,13.05,10]octa­decane-18′,2′′-[1,3]dioxolane]-7′,15′-diene

The title compound, C22H28O4, is composed of a central octa­decane ring and two spiro­[bicyclo­[2.2.1]hept[2]ene-7,2′-[1,3]dioxolane] units. This polycycle has pseudo twofold symmetry and the central cyclo­octane ring has a distorted boat configuration

Оценка нестационарной теплоотдачи при пленочной конденсации пара на вертикальной стенке

Получены расчетные зависимости коэффициента теплоотдачи, скорости движения и трансцендентное уравнение для толщины ламинарной пленки конденсата, справедливые для регулярного теплового режима

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial

© 2016 AGA Institute Background & Aims Studies are needed to determine the optimal regimen for patients with chronic hepatitis C virus (HCV) genotype 2, 3, 4, or 6 infections whose prior course of antiviral therapy has failed, and the feasibility of shortening treatment duration. We performed a phase 2 study to determine the efficacy and safety of the combination of the nucleotide polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the NS3/4A protease inhibitor GS-9857 in these patients. Methods We performed a multicenter, open-label trial at 32 sites in the United States and 2 sites in New Zealand from March 3, 2015 to April 27, 2015. Our study included 128 treatment-naïve and treatment-experienced patients (1 with HCV genotype 1b; 33 with HCV genotype 2; 74 with HCV genotype 3; 17 with genotype HCV 4; and 3 with HCV genotype 6), with or without compensated cirrhosis. All patients received sofosbuvir-velpatasvir (400 mg/100 mg fixed-dose combination tablet) and GS-9857 (100 mg) once daily for 6–12 weeks. The primary end point was sustained virologic response 12 weeks after treatment (SVR12). Results After 6 weeks of treatment, SVR12s were achieved by 88% of treatment-naïve patients without cirrhosis (29 of 33; 95% confidence interval, 72%–97%). After 8 weeks of treatment, SVR12s were achieved by 93% of treatment-naïve patients with cirrhosis (28 of 30; 95% CI, 78%–99%). After 12 weeks of treatment, SVR12s were achieved by all treatment-experienced patients without cirrhosis (36 of 36; 95% CI, 90%–100%) and 97% of treatment-experienced patients with cirrhosis (28 of 29; 95% CI, 82%–100%). The most common adverse events were headache, diarrhea, fatigue, and nausea. Three patients (1%) discontinued treatment due to adverse events. Conclusions In a phase 2 open-label trial, we found sofosbuvir-velpatasvir plus GS-9857 (8 weeks in treatment-naïve patients or 12 weeks in treatment-experienced patients) to be safe and effective for patients with HCV genotype 2, 3, 4, or 6 infections, with or without compensated cirrhosis. ClinicalTrials.gov ID: NCT02378961